ganulameran (BNT162b3) / Pfizer, Fosun Pharma, BioNTech - LARVOL DELTA

Toxicological Assessments of a Pandemic COVID-19 Vaccine-Demonstrating the Suitability of a Platform Approach for mRNA Vaccines. (PubMed, Vaccines (Basel)) - "These findings were generally attributed to the anticipated immune and inflammatory responses to the vaccines, except for hepatocyte vacuolation, which was interpreted to reflect hepatocyte LNP lipid uptake, was similar between candidates and resolved or partially recovered at the end of the recovery phase. These studies demonstrated safety and tolerability in rats, supporting SARS-CoV-2 mRNA-LNP vaccine clinical development."

Journal • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases

A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults (clinicaltrials.gov) - P1/2 | N=96 | Completed | Sponsor: BioNTech SE | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

"Was it ever revealed what #BNT162b3 encodes? @florian_krammer @pfizer" (@LordAlirezaF)

A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults (clinicaltrials.gov) - P1/2; N=96; Active, not recruiting; Sponsor: BioNTech SE; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults (clinicaltrials.gov) - P1/2; N=120; Recruiting; Sponsor: BioNTech SE; Trial primary completion date: Sep 2021 ➔ Mar 2021

Clinical • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

"Wondering if @florian_krammer or anyone else has any information about the BNT162b3 construct?" (@aruby_)

A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults (clinicaltrials.gov) - P1/2; N=120; Not yet recruiting; Sponsor: BioNTech RNA Pharmaceuticals GmbH

Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease

A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults (clinicaltrials.gov) - P1/2; N=120; Recruiting; Sponsor: BioNTech RNA Pharmaceuticals GmbH; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease